Vladonix
What is it?
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Identity / background source ↗
Research context
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
- Working classification
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
- Study methods
- —Small comparative institute report; allocation, blinding and outcome interpretation require caution
- Independent replication
- —Independent replication not established in this collection
- Source access
- —Report reproduction linked; source language and review scope shown per record
- Safety evidence
- —Short-term reports do not establish long-term safety or equivalence to current products
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Explore the expanded peptide research collection and unresolved source trails ↗
View this preparation in the Khavinson evidence map ↗
Linked sources
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Explore the research map and unresolved leads ↗
Vladonix: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes lymphocyte and immunoglobulin measurements after 15–20 days. Table significance is relative to baseline.
- Population / setting
- 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- Sex counts differ between prose and table. Immune biomarkers do not establish protection from radiation, fewer infections or improved cancer outcomes.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.